Stock DIVISLAB DIVI'S LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Divi's Laboratories Limited

Equities

DIVISLAB

INE361B01024

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:47 2024-04-26 am EDT 		5-day change 1st Jan Change
4,016 INR +4.49% Intraday chart for Divi's Laboratories Limited +9.39% +2.88%
Apr. 26 Weak March Quarter Earnings Weigh Down Indian Equities on Friday MT
Apr. 25 Divi's Laboratories Plans Up To INR7 Billion Investment to Boost Capacity MT

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 452,120 528,030 961,740 1,168,606 749,511 1,066,215 - -
Enterprise Value (EV) 1 438,040 527,140 940,228 1,140,454 707,412 1,020,181 1,017,888 1,012,788
P/E ratio 33.4 x 38.4 x 48.5 x 39.5 x 41.1 x 69 x 52.2 x 42.1 x
Yield 0.94% 0.8% 0.55% 0.68% 1.06% 0.64% 0.71% 0.79%
Capitalization / Revenue 9.14 x 9.79 x 13.8 x 13 x 9.65 x 13.9 x 12 x 10.4 x
EV / Revenue 8.86 x 9.77 x 13.5 x 12.7 x 9.11 x 13.3 x 11.5 x 9.88 x
EV / EBITDA 23.4 x 28.9 x 32.9 x 29.4 x 29.9 x 48.5 x 36.4 x 29.3 x
EV / FCF 198 x 1,611 x 90.7 x 95.1 x 35.6 x 113 x 130 x 81.1 x
FCF Yield 0.51% 0.06% 1.1% 1.05% 2.81% 0.88% 0.77% 1.23%
Price to Book 6.5 x 7.22 x 10.4 x 9.96 x 5.87 x 7.96 x 7.28 x 6.54 x
Nbr of stocks (in thousands) 265,469 265,469 265,469 265,469 265,469 265,469 - -
Reference price 2 1,703 1,989 3,623 4,402 2,823 4,016 4,016 4,016
Announcement Date 5/25/19 6/6/20 5/29/21 5/23/22 5/20/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 49,463 53,944 69,694 89,598 77,675 76,786 88,633 102,505
EBITDA 1 18,718 18,222 28,599 38,819 23,678 21,056 27,992 34,603
EBIT 1 17,029 16,359 26,044 35,704 20,246 17,524 24,027 30,233
Operating Margin 34.43% 30.33% 37.37% 39.85% 26.07% 22.82% 27.11% 29.49%
Earnings before Tax (EBT) 1 18,551 18,195 26,660 36,835 23,686 20,603 27,420 33,831
Net income 1 13,527 13,765 19,843 29,604 18,234 15,380 20,376 25,114
Net margin 27.35% 25.52% 28.47% 33.04% 23.47% 20.03% 22.99% 24.5%
EPS 2 50.96 51.85 74.75 111.5 68.69 58.25 76.95 95.38
Free Cash Flow 1 2,212 327.3 10,367 11,986 19,867 9,008 7,804 12,484
FCF margin 4.47% 0.61% 14.88% 13.38% 25.58% 11.73% 8.81% 12.18%
FCF Conversion (EBITDA) 11.82% 1.8% 36.25% 30.88% 83.9% 42.78% 27.88% 36.08%
FCF Conversion (Net income) 16.35% 2.38% 52.25% 40.49% 108.96% 58.57% 38.3% 49.71%
Dividend per Share 2 16.00 16.00 20.00 30.00 30.00 25.59 28.40 31.81
Announcement Date 5/25/19 6/6/20 5/29/21 5/23/22 5/20/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 17,014 17,882 19,606 19,875 24,932 25,184 22,545 18,545 17,077 19,508 17,780 19,312 19,926 20,742 20,927
EBITDA 1 6,912 7,163 8,520 8,181 10,972 11,044 8,467 6,210 4,083 4,876 5,040 5,837 5,649 6,011 -
EBIT 1 6,230 6,462 7,788 7,407 10,173 10,234 7,630 5,353 3,215 4,006 4,110 4,948 4,786 4,674 5,169
Operating Margin 36.62% 36.14% 39.72% 37.27% 40.8% 40.64% 33.84% 28.86% 18.83% 20.53% 23.12% 25.62% 24.02% 22.53% 24.7%
Earnings before Tax (EBT) 1 6,421 - 8,145 7,596 10,337 10,757 8,513 6,152 4,356 4,665 4,920 5,611 5,351 5,827 -
Net income 1 4,706 5,020 5,571 6,065 9,029 8,946 7,020 4,936 3,068 3,210 3,560 4,264 4,134 4,442 -
Net margin 27.66% 28.07% 28.41% 30.51% 36.21% 35.52% 31.14% 26.62% 17.97% 16.45% 20.02% 22.08% 20.75% 21.42% -
EPS 2 17.73 18.91 20.99 22.84 33.99 33.70 26.44 18.60 11.56 12.09 13.41 15.34 15.73 15.94 -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/6/21 5/29/21 8/7/21 11/6/21 2/11/22 5/23/22 8/12/22 11/7/22 2/3/23 5/20/23 8/14/23 - - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 14,080 890 21,512 28,152 42,098 46,034 48,326 53,427
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 2,212 327 10,367 11,986 19,867 9,008 7,805 12,484
ROE (net income / shareholders' equity) 21% 19.3% 21% 28.2% 14.9% 11.7% 14.2% 16%
ROA (Net income/ Total Assets) 18.3% - 20.6% 24.5% 13.1% 9.65% 13% 15%
Assets 1 74,120 - 96,550 120,744 139,067 159,380 156,736 167,426
Book Value Per Share 2 262.0 275.0 349.0 442.0 481.0 505.0 552.0 614.0
Cash Flow per Share 2 35.90 45.80 73.30 72.00 92.70 65.50 75.40 92.90
Capex 1 7,331 11,832 9,102 7,132 4,730 10,155 9,710 9,091
Capex / Sales 14.82% 21.93% 13.06% 7.96% 6.09% 13.23% 10.95% 8.87%
Announcement Date 5/25/19 6/6/20 5/29/21 5/23/22 5/20/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Divi's Laboratories Limited

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
4,016 INR
Average target price
3,442 INR
Spread / Average Target
-14.29%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
DIVI'S LABORATORIES LIMITED Stock Divi's Laboratories Limited
+2.88% 12.78B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. DIVISLAB Stock
  4. Financials Divi's Laboratories Limited